Analytical Data
-
Gene name
KAT2A
- Application
-
Alternative Names
GCN5L2; GCN5; PCAF-b; hGCN5; GCN5; STAF97; Lysine acetyltransferase 2A; Histone acetyltransferase GCN5; General Control Of Amino-Acid Synthesis 5-Like 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92830
-
Expression Region
Ala648~Lys837
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KAT2A, or Lysine Acetyltransferase 2A, is a crucial enzyme involved in the regulation of gene expression through histone acetylation, a post-translational modification that alters chromatin structure and subsequently influences transcriptional activity. This enzyme plays a vital role in various cellular processes, including cell differentiation, proliferation, and metabolism. Dysregulation of KAT2A has been implicated in several diseases, including cancer, where it may contribute to the aberrant expression of oncogenes and tumor suppressors. As research on epigenetics gains momentum, KAT2A has emerged as a potential target for therapeutic interventions aimed at reversing abnormal gene expression patterns observed in various pathologies. The study of recombinant KAT2A protein allows for a deeper understanding of its enzymatic mechanisms, substrate specificity, and interactions with other proteins within the context of the acetylation cycle. This research not only enhances the fundamental knowledge of KAT2A's function but also paves the way for the development of small-molecule inhibitors or activators that could be harnessed for clinical applications. Understanding KAT2A's role in health and disease could lead to innovative strategies for targeted therapies in cancer and other disorders related to epigenetic modifications.
